Vor Biopharma Inc

NASDAQ VOR

Data sourced from

and

Download Data

Vor Biopharma Inc Revenue Per Share for the year ending December 31, 2023: USD 0.00

Vor Biopharma Inc Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Vor Biopharma Inc Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a 0.00% change year over year.
Vor Biopharma Inc Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a 0.00% change year over year.
Vor Biopharma Inc Revenue Per Share for the year ending December 31, 2020 was USD 0.00, a 0.00% change year over year.
Vor Biopharma Inc Revenue Per Share for the year ending December 31, 2019 was USD 0.00, a 0.00% change year over year.

NASDAQ: VOR

Vor Biopharma Inc

CEO	Dr. Robert Ang M.B.A., M.D., MBBS
IPO Date	Feb. 5, 2021
Location	United States
Headquarters	100 Cambridgepark Drive, Cambridge, MA, United States, 02140
Employees	168
Sector	Healthcare
Industry	Biotechnology

Description

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Key trends